Your session is about to expire
Evekeo vs Mydayis
Introduction
For patients suffering from Attention Deficit Hyperactivity Disorder (ADHD) or narcolepsy, certain stimulants that alter the concentrations of compounds in the brain related to focus and attention can be helpful. Evekeo and Mydayis are two such medications used for these conditions. They each impact different neurotransmitters in the brain but both have effects on improving concentration and reducing hyperactivity in patients with ADHD. Evekeo is a racemic mixture of amphetamine salts, affecting levels of dopamine and norepinephrine. On the other hand, Mydayis is an extended-release formulation containing mixed amphetamine salts primarily affecting levels of dopamine while also influencing serotonin to some extent.
Evekeo vs Mydayis Side By Side
| Attribute | Evekeo | Mydayis |
|---|---|---|
| Brand Name | Evekeo | Mydayis |
| Contraindications | Should not be taken with MAOIs or by individuals with cardiovascular disease or severe hypertension | Should not be taken with MAOIs or by individuals with cardiovascular disease or severe hypertension |
| Cost | Approximately $1.70 to $6.80 per day for generic versions | Approximately $2.30 to $9.30 per day for generic versions |
| Generic Name | Amphetamine Sulfate | Mixed Amphetamine Salts XR |
| Most Serious Side Effect | Severe anxiety, paranoia, or agitation; heart-related issues; vision problems; circulation problems; neurological symptoms | Signs of an allergic reaction; mental/mood changes; chest pain; seizure activities; blurred vision; unusual behavior changes and confusion; hallucinations |
| Severe Drug Interactions | Monoamine oxidase inhibitors (MAOIs) | Monoamine oxidase inhibitors (MAOIs) |
| Typical Dose | Adults start at 5 mg twice daily, before breakfast and lunch. Children 3-5 years old start at 2.5 mg daily; over six start at 5 mg once or twice a day. | Initiated at 12.5 mg once daily in the morning. Dose may be increased by increments of 12.5 mg, up to a maximum of 50 mg for adults and 25mg for pediatric patients aged 13 to 17 years old. |
What is Evekeo?
Evekeo and Mydayis are both stimulant medications used in the treatment of attention deficit hyperactivity disorder (ADHD). Evekeo, which is a brand name for amphetamine sulfate, was first approved by the FDA in 2014. This medication works to increase levels of dopamine and norepinephrine in the brain, effectively "boosting" their activity for longer durations than usual. It's typically prescribed for ADHD as well as narcolepsy.
On the other hand, Mydayis is an extended-release version of mixed amphetamine salts that was approved by the FDA in 2017. While it also increases dopamine and norepinephrine levels like Evekeo, its impact lasts significantly longer due to its three-bead delivery system designed to release medication throughout the day gradually.
Both drugs may cause similar side effects due to their influence on these neurotransmitters; however, Mydayis tends to have stronger effects because of its prolonged action time and may lead to more noticeable side effects such as insomnia or decreased appetite.
What conditions is Evekeo approved to treat?
Evekeo is approved for the treatment of various conditions including:
- Attention-deficit/hyperactivity disorder (ADHD) in pediatric patients 3 years and older
- Narcolepsy, a neurological disorder that affects the control of sleep and wakefulness
- Exogenous obesity as a short term adjunct in a regimen of weight reduction based on caloric restriction, for patients with initial body mass index greater than or equal to 30 kg/m2 who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone.
How does Evekeo help with these illnesses?
Evekeo and Mydayis are both stimulant medications used to manage Attention-Deficit Hyperactivity Disorder (ADHD). They function by increasing the amounts of dopamine and norepinephrine available in the synapses of the brain. These two neurotransmitters play crucial roles in regulating attention, impulsivity, and activity levels.
In people with ADHD, it is thought that these neurotransmitter levels may be relatively low or imbalanced. Therefore, by enhancing their availability in the brain's synaptic gaps, Evekeo and Mydayis can help counteract symptoms of ADHD such as difficulty focusing or controlling impulses.
While they share a similar mechanism of action, there are some key differences between these two drugs. For instance, while Evekeo contains amphetamine sulfate—a mix of different types of amphetamines—Mydayis contains mixed salts containing different forms of amphetamine which leads to its prolonged effect due to its slow release formulation.
What is Mydayis?
Mydayis is a brand name for a mixed amphetamine salts product, which works as a central nervous system (CNS) stimulant by increasing the levels of dopamine and norepinephrine in the brain through their release from nerve endings. It also blocks their reuptake into nerves. Mydayis, available since 2017, is not an NDRI like bupropion or Evekeo; it has broader action on multiple neurotransmitters including serotonin to some extent. Its effects on both dopamine and norepinephrine make it beneficial for treating attention-deficit/hyperactivity disorder (ADHD), particularly in patients who do not respond well to other medications such as Evekeo. However, its increased activity compared with medications that primarily target either dopamine or norepinephrine means that its side-effect profile differs: common side effects include insomnia and decreased appetite rather than drowsiness or weight gain often seen with selective serotonin reuptake inhibitors (SSRIs).
What conditions is Mydayis approved to treat?
Mydayis is a once-daily treatment that has been approved by the FDA for:
- Attention deficit hyperactivity disorder (ADHD) in patients 13 years and older
- Narcolepsy, which is characterized by excessive daytime sleepiness, cataplexy, hallucinations, and sleep paralysis
How does Mydayis help with these illnesses?
Dopamine is a neurotransmitter that plays key roles in how we feel pleasure and motivation, among other functions. It's heavily involved in attention and focus, which are often impaired in conditions like ADHD. Mydayis works by increasing the levels of dopamine available in the brain to help alleviate some of the symptoms associated with ADHD such as lack of focus, impulsivity, and hyperactivity. This medication acts on norepinephrine too - another neurotransmitter implicated in attentional control. Unlike Evekeo which has a shorter duration of action, Mydayis provides sustained effects over an extended period due to its unique formulation. Therefore it may be more beneficial for individuals who struggle with maintaining concentration throughout the day or those who don't respond optimally to shorter-acting stimulants like Evekeo.
How effective are both Evekeo and Mydayis?
Both amphetamine sulfate (Evekeo) and mixed amphetamine salts (Mydayis) are used to treat ADHD, and they were initially approved by the FDA several years apart. Since they affect different proportions of neurotransmitters, they may be prescribed under varying circumstances. A direct comparison between Evekeo and Mydayis is difficult due to lack of head-to-head clinical trials; however, both drugs have shown efficacy in managing symptoms related to ADHD.
A meta-analysis report on Evekeo showed it was effective in alleviating ADHD symptoms from the first dose onwards, with a favorable side effect profile compared to other stimulant medications. As one of the few medications containing a balanced mix of amphetamine salts (50% levoamphetamine and 50% dextroamphetamine), it offers unique benefits such as potentially improved control over hyperactivity-impulsivity symptoms. The optimal dosage varies greatly based on individual needs but often lies within the range of 5-40 mg per day for adults.
On the other hand, Mydayis contains a blend of three types of amphetamines which leads to its extended-release formulation offering up to 16 hours coverage against ADHD symptoms - longer than most other comparable treatments. This long-lasting effectiveness makes it ideal for patients who require symptom control throughout their waking hours without needing multiple doses during the day.
While significant research involving Evekeo or Mydayis usually involves them being co-prescribed alongside non-stimulant medications targeted towards comorbid conditions like anxiety or depression, data confirming their efficacy as standalone treatments is relatively robust due to numerous controlled studies conducted over decades since their introduction into medicinal use.
However, keep in mind that while these two drugs can be highly effective at treating ADHD when taken correctly under medical supervision, misuse can lead serious health issues including dependency so always consult your healthcare provider before making changes in medication regimen.
Find Top Clinical Trials
Choose from over 30,000 active clinical trials.
At what dose is Evekeo typically prescribed?
Oral dosages of Evekeo for treating ADHD in adults typically start at 5 mg twice daily, before breakfast and lunch. For children aged 3-5 years old, the starting dosage is usually 2.5 mg daily; for those over six, it begins with 5 mg once or twice a day. The dose can be increased by increments of 2.5 to 10 mg weekly until an optimal response is achieved.
On the other hand, Mydayis is designed to be taken once daily due to its extended release formulation. It's typically initiated at a dosage of 12.5mg/day in adolescents (13-17 years) and adults with ADHD and this can gradually be increased up to a maximum dose of approximately 50mg/day based on individual patient response and tolerability.
In either case, these medications should only be used under close medical supervision given their potential for serious side effects including dependency.
At what dose is Mydayis typically prescribed?
Mydayis treatment is typically initiated at a dosage of 12.5 mg once daily in the morning upon waking. The dose may then be increased on a weekly basis by increments of 12.5 mg, depending on individual patient response and tolerability. The maximum recommended daily dose is 50 mg for adults and 25mg for pediatric patients aged 13 to 17 years old, which can be considered if there's no significant improvement with lower doses after several weeks. It should not be taken in the late afternoon or evening due to its potential impact on sleep as Mydayis has an extended release mechanism designed to provide symptom control throughout the day.
What are the most common side effects for Evekeo?
Common side effects of Evekeo and Mydayis can include:
- Increased heart rate
- Elevated blood pressure
- Anxiety, nervousness
- Insomnia (trouble sleeping)
- Decreased appetite, weight loss
- Dry mouth
- Tremor (unintentional trembling or shaking)
- Stomach pain, nausea
- Diarrhea or constipation
- Dizziness or lightheadedness
Decreased libido (sex drive), impotence are less common but possible side effects. Rarely patients might experience symptoms like palpitations, shortness of breath and excessive sweating. It is important to note that not everyone experiences these side effects and they often lessen over time as the body becomes used to the medication. However, if any of these occur it's crucial to consult with a healthcare provider promptly.
Are there any potential serious side effects for Evekeo?
Both Evekeo and Mydayis are stimulant medications often used to treat attention deficit hyperactivity disorder (ADHD). Potential severe side effects of both drugs include:
- Severe anxiety, paranoia, or agitation
- Allergic reactions: hives, difficulty breathing, swelling in your face or throat
- Heart-related issues: rapid heartbeat, chest pain and shortness of breath
- Vision problems: blurred vision or changes in vision
- Circulation problems - numbness, pain, cold feeling, unexplained wounds or color changes on fingers/toes
- Neurological symptoms – headache with dizziness; fainting; weakness on one side of the body; unsteady movement; seizure.
Additionally these drugs can exacerbate mental health issues leading to thoughts about suicide or self-harm. Any unusual mood swings should be reported immediately.
In children they may impede growth so regular monitoring is needed. If you notice any alarming symptom while taking either medication it's crucial to contact a healthcare professional right away.
What are the most common side effects for Mydayis?
Potential side effects of Mydayis can include:
- Dry mouth and unpleasant taste in the mouth
- Loss of appetite, leading to weight loss
- Stomach pain, nausea or vomiting
- Diarrhea or constipation
- Sleep problems such as insomnia
- Restlessness and jitteriness
- Increased heart rate or blood pressure
- Sweating more than usual
- Dizziness, mild headache
- Mood swings, feeling nervous or irritable. Remember that this is not an exhaustive list and it's always recommended to consult with your healthcare provider about potential side effects before starting any new medication.
Are there any potential serious side effects for Mydayis?
Mydayis, similar to other medications used for the treatment of attention deficit hyperactivity disorder (ADHD), can have several potentially serious side effects. These may include:
- Signs of an allergic reaction such as hives; difficulty breathing; swelling in your face, lips, tongue or throat
- Mental/mood changes like aggression, mood swings or depression including thoughts about suicide or self-harm
- Chest pain, palpitations and irregular heartbeats indicative of cardiovascular reactions
- Seizure activities that might be new or worsening
- Blurred vision and eye issues which could indicate circulation problems
- Unusual behavior changes and confusion
- Hallucinations – hearing/seeing things that are not real In case you experience any of these symptoms while taking Mydayis, it is important to seek immediate medical assistance.
Contraindications for Evekeo and Mydayis?
Both Evekeo and Mydayis, similar to other stimulant medications, may exacerbate symptoms of anxiety or nervousness in some individuals. If you notice your anxiety increasing, or an escalation in agitation, restlessness, or insomnia while taking these medications, please seek immediate medical attention.
Neither Evekeo nor Mydayis should be taken if you have recently used a monoamine oxidase inhibitor (MAOI). Always inform your healthcare provider about all the medicines you are currently taking; MAOIs will require a clearance period of about 14 days to prevent dangerous interactions with Evekeo and Mydayis.
Evekeo and Mydayis can also lead to increased heart rate and blood pressure. Therefore it is not advisable for people with cardiovascular disease or severe hypertension to use them. It's important that patients communicate their full health history with their physician before starting either medication.
How much do Evekeo and Mydayis cost?
For the brand name versions of these drugs:
- The price of 60 tablets of Evekeo (5 mg) averages around $250, which works out to $8.30/day, depending on your dose.
- The price of 30 capsules of Mydayis (12.5 mg) averages around $280, working out to approximately $9.30/day.
Thus, if you are in the higher dosage range for Evekeo (i.e., 20 mg/day or higher), then brand-name Mydayis is less expensive on a per-day treatment basis. Please note that cost should not be a primary consideration in determining which of these drugs is right for you.
As for the generic versions of these drugs, costs are significantly lower:
- Evekeo (5 mg tablets) is available in packs of 30 tablets and above, with approximate costs of $1.70 to $3.40 per day for dosages of 5 mg/day, or between $3.40 and $6.80 per day if you are taking more typical dosages of 10 to 20 mg/day.
- Mydayis is available in packs of 15 up to 60 capsules (12.5 mg), with the cost to you starting from as low as $2.30/day (if you buy the largest pack upfront), and not exceeding about $9.30/day.
Popularity of Evekeo and Mydayis
Evekeo and Mydayis are both powerful medications primarily used for the treatment of attention deficit hyperactivity disorder (ADHD).
In 2020, Evekeo was prescribed to approximately 40,000 patients in the United States. This stimulant medication accounts for just over 1% of all ADHD prescriptions. Evekeo is a branded medication that contains amphetamine sulfate as its active ingredient. The prevalence of Evekeo has been relatively consistent since it was approved by the FDA in 2012.
On the other hand, Mydayis, which includes three different types of amphetamine salts as its active ingredients, was prescribed to around 150,000 people in the USA during 2020. In terms of overall ADHD prescriptions within the country, Mydayis represents about 3%. Its usage has seen an increase since being introduced to market in mid-2017.
Conclusion
Both Evekeo (amphetamine sulfate) and Mydayis (mixed amphetamine salts) are used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), with a long-standing record of usage and numerous clinical studies indicating their effectiveness over placebo treatments. In some cases, these drugs may be combined or used alongside other ADHD medications, though this requires careful consideration by a physician due to potential interactions. Both work primarily on dopamine and norepinephrine neurotransmitters but differ in terms of their salt composition which impacts duration of action.
Evekeo is often considered as an initial choice for therapy because it has a shorter half-life, allowing flexibility in determining the best dosing schedule for each individual patient. Mydayis, however, contains three different types of amphetamine salts that provide extended release covering up to 16 hours per day making it more suitable for those who need longer symptom control.
Both drugs are available in generic form—Evekeo as Amphetamine Sulfate and Mydayis as mixed amphetamine salts XR—which can offer significant cost savings especially for patients paying out-of-pocket. It's worth noting both Evekeo and Mydayis might require time before reaching full therapeutic effects.
The side effect profile is similar between the two drugs; common ones include decreased appetite, insomnia, abdominal pain etc., but they're generally well-tolerated if taken correctly. However, patients should closely monitor any mood changes or cardiovascular symptoms while starting treatment with either drug; seeking immediate medical help if adverse reactions occur.